Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

Avalanche Biotechnologies (2014a). Avalanche Biotechnologies announces closing of initial public offering and exercise of underwriters' option to purchase additional shares. Available at http://money.cnn.com/news/newsfeeds/articles/globenewswire/10092935.htm (accessed August 5, 2014).

Avalanche Biotechnologies (2014b). Avalanche Biotechnologies secures $55 million in oversubscribed series B financing. Available at http://investors.avalanchebiotech.com/phoenix.zhtml?c=253634&p=irol-newsArticle&ID=1952745&highlight= (accessed August 4, 2014).

Cedars-Sinai (2014). Transplanting gene into injured hearts creates biological pacemakers. Available at http://cedars-sinai.edu/About-Us/News/News-Releases-2014/Transplanting-Gene-into-Injured-Hearts-Creates-Biological-Pacemakers.aspx (accessed August 5, 2014).

Celladon (2014). Celladon Corporation announces in-license of Stem Cell Factor development program. Available at http://ir.celladon.net/releasedetail.cfm?ReleaseID=860817 (accessed August 6, 2014).

Cellectis (2014a). Cellectis sells its Swedish subsidiary, Cellectis AB, to the Japanese company Takara Bio Inc. Available at www.cellectis.com/sites/default/files/pr_takara_en_final_0.pdf (accessed August 4, 2014).

Cellectis (2014b). Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors. Available at www.cellectis.com/en/content/cellectis-and-servier-announce-collaboration-allogeneic-cell-therapy-ucart19-treat-leukemi-0 (accessed August 5, 2014).

, Dawkins

J.F.

, Cho

H.C.

, et al. (2014). Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci. Transl. Med., 6, 245ra94.

Pfizer (2014). Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration. Available at http://press.pfizer.com/press-release/pfizer-and-cellectis-enter-global-strategic-cancer-immunotherapy-collaboration (accessed August 6, 2014).

Regeneron Pharmaceuticals and Avalanche Biotechnologies (2014). Regeneron and Avalanche Biotechnologies announce collaboration to develop next-generation gene therapy products in ophthalmology. Available at http://investor.regeneron.com/releasedetail.cfm?ReleaseID=845170 (accessed August 6, 2014).

10.

U.S. Food and Drug Administration (2014). Draft guidance for industry: Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products. Available at www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM404087.pdf (accessed August 4, 2014).

11.

U.S. Securities and Exchange Commission (2014a). Form S-1, Registration Statement for Avalanche Biotechnologies. Available at http://investors.avalanchebiotech.com/phoenix.zhtml?c=253634&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9OTY3OTYwMiZzdWJzaWQ9NTc%3d&ListAll=1 (accessed August 4, 2014).

12.

U.S. Securities and Exchange Commission (2014b). Form 8-K for Celladon Corp., Entry into a material definitive agreement, financial statements and exhibits. Available at http://ir.celladon.com/secfiling.cfm?filingID=1193125-14-274285&CIK=1305253 (accessed August 6, 2014).

13.

University of Pennsylvania (2014). University of Pennsylvania's personalized cellular therapy for leukemia receives FDA's Breakthrough Therapy designation. Available at www.uphs.upenn.edu/news/News_Releases/2014/07/ctl019/ (accessed August 5, 2014).